The chief medical officer of a drug pricing watchdog is warning against the FDA granting full approval to drugs that were previously granted accelerated approval if they then go on to fail ...
Ahead of the FDA’s June target action date for Sarepta’s Duchenne muscular dystrophy gene therapy, ICER Chief Medical Officer David Rind blasted the regulator’s accelerated pathway in a JAMA viewpoint ...